Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 145

Sort by

Sort Order Select

Journal Articles

Extracellular Release of Damaged Mitochondria Induced By Cytotoxic Conditioning Exacerbates Graft-Versus-Host Disease

Vijith Vijayan, Hao Yan, Juliane Lohmeyer, Kaylin Prentiss, Rachana Patil, Giulia Barbarito, Ivan Lopez, Aly Elezaby, Kolten Peterson, Jeanette Baker, Nicolai Ostberg, Alice Bertaina, Robert S. Negrin, Daria Mochly-Rosen, Kenneth I. Weinberg, Bereketeab Haileselassie

Blood (2023) 142 (Supplement 1): 2051.

https://doi.org/10.1182/blood-2023-179456

Published: 2023

Journal Articles

CAR19 Therapy Drives Expansion of Clonal Hematopoiesis and Associated Cytopenias

Blood (2023) 142 (Supplement 1): 360.

https://doi.org/10.1182/blood-2023-182522

Published: 2023

Journal Articles

Heterogeneity of Human Invariant Natural Killer T Cells, Including Novel Naïve-like CD8 + and Temra-like CD4 - CD8 - Populations, Revealed through Single Cell RNA-Sequencing

Melissa Mavers, Derek Hollingsworth, Reyka G. Jayasinghe, Chaiyaporn Boonchalermvichian, Biki Gupta, Hao Yan, Jeanette Baker, Beruh Dejene, Kenneth I. Weinberg, Robert S. Negrin

Blood (2023) 142 (Supplement 1): 152.

https://doi.org/10.1182/blood-2023-182442

Published: 2023

Journal Articles

Optimizing Outcomes with Myeloablative Conditioning in Older Patients: Efficacy and Safety of Precision Engineered Orca-T in Patients > 55 Years Old with Hematologic Malignancies

Caspian H. Oliai, Jeremy M. Pantin, Rasmus T. Hoeg, Lori S. Muffly, Sagar S. Patel, Arpita Gandhi, Robert Lowsky, Amandeep Salhotra, Bhagirathbhai Dholaria, Edmund K. Waller, Samer A. Srour, Anna Pavlova, Nathaniel B. Fernhoff, Irene Agodoa, J. Scott McClellan, Mehrdad Abedi, Robert S. Negrin, Everett H. Meyer

Blood (2023) 142 (Supplement 1): 230.

https://doi.org/10.1182/blood-2023-186749

Published: 2023

Journal Articles

Phase 1 Trial Results for Patients with Advanced Hematologic Malignancies Undergoing Reduced Intensity Allogeneic HCT with Orca-T Donor Cell Therapy Product and Single Agent Tacrolimus

Blood (2023) 142 (Supplement 1): 3560.

https://doi.org/10.1182/blood-2023-188162

Published: 2023

Journal Articles

Improved outcomes for relapsed/refractory Hodgkin lymphoma after autologous transplantation in the era of novel agents

Michael A. Spinner, R. A. Sica, John S. Tamaresis, Ying Lu, Cheryl Chang, Robert Lowsky, Matthew J. Frank, Laura J. Johnston, David B. Miklos, Lori S. Muffly, Robert S. Negrin, Andrew R. Rezvani, Parveen Shiraz, Judith A. Shizuru, Wen-Kai Weng, Michael S. Binkley, Richard T. Hoppe, Ranjana H. Advani, Sally Arai

Blood (2023) 141 (22): 2727–2737.

https://doi.org/10.1182/blood.2022018827

Published: 2023

Includes: Supplemental data

Journal Articles

Analysis of the T-cell repertoire and transcriptome identifies mechanisms of regulatory T-cell suppression of GVHD

Juliane K. Lohmeyer, Toshihito Hirai, Mustafa Turkoz, Stephane Buhler, Teresa Lopes Ramos, Natalie Köhler, Jeanette Baker, Astrid Melotti, Ingrid Wagner, Amandine Pradier, Sisi Wang, Xuhuai Ji, Simone Becattini, Jean Villard, Doron Merkler, Yves Chalandon, Robert S. Negrin, Federico Simonetta

Blood (2023) 141 (14): 1755–1767.

https://doi.org/10.1182/blood.2022017982

Published: 2023

Includes: Supplemental data

Journal Articles

Prevention of acute GVHD using an orthogonal IL-2/IL-2Rβ system to selectively expand regulatory T cells in vivo

Blood (2023) 141 (11): 1337–1352.

https://doi.org/10.1182/blood.2022018440

Published: 2023

Includes: Supplemental data

Journal Articles

Precision-Engineered Cell Therapy Orca-T Demonstrates High Relapse-Free Survival at 1 Year While Reducing Graft-Versus-Host Disease and Toxicity

Blood (2022) 140 (Supplement 1): 654–656.

https://doi.org/10.1182/blood-2022-165654

Published: 2022

Journal Articles

Belumosudil Combination Therapy in Refractory Chronic Graft-Versus-Host Disease

Michelle Chin, Judith A. Shizuru, Lori Muffly, Parveen Shiraz, Laura J. Johnston, Robert Lowsky, Andrew R. Rezvani, Matthew J. Frank, Sushma Bharadwaj, Wen-Kai Weng, Robert S. Negrin, David B. Miklos, Sally Arai

Blood (2022) 140 (Supplement 1): 4788–4789.

https://doi.org/10.1182/blood-2022-165547

Published: 2022

Journal Articles

The Development of Carhlh after Axicabtagene Ciloleucel Is Associated with Poor Outcomes

Blood (2022) 140 (Supplement 1): 12775–12777.

https://doi.org/10.1182/blood-2022-170877

Published: 2022

Journal Articles

Analysis of Bendamustine Lymphodepletion, CD19 CART Expansion, Safety and Efficacy in Patients with Rel/Ref Non-Hodgkin Lymphoma

Blood (2022) 140 (Supplement 1): 10371–10373.

https://doi.org/10.1182/blood-2022-170759

Published: 2022

Journal Articles

Higher Rates of Severe Infection and Persistent Cytopenias in Long-Term CAR19 Responders Than after Autologous HCT: A Single Institution Study of 139 Subjects

Blood (2022) 140 (Supplement 1): 7545–7547.

https://doi.org/10.1182/blood-2022-165600

Published: 2022

Journal Articles

Outcomes for Acute Myeloid Leukemia Relapse after Allogeneic Hematopoietic Cell Transplantation Remain Poor in the Modern Era

Shona Philip, Robert Lowsky, Laura J. Johnston, Sally Arai, Everett H. Meyer, Robert S. Negrin, Andrew R. Rezvani, Parveen Shiraz, Judith A. Shizuru, Surbhi Sidana, Wen-Kai Weng, Sushma Bharadwaj, Matthew J. Frank, David B. Miklos, Melody Smith, Lori Muffly, Vaibhav Agrawal

Blood (2022) 140 (Supplement 1): 4825–4827.

https://doi.org/10.1182/blood-2022-168546

Published: 2022

Journal Articles

Outcomes for Myelofibrosis Patients Following Myeloablative Allogeneic Stem Cell Transplantation Using the Orca-T Graft from HLA-Matched Related and Unrelated Donors

Arpita Gandhi, Anna Moroz, Lori Muffly, Parveen Shiraz, Levanto Schachter, Nathaniel B Fernhoff, J Scott McClellan, Robert S. Negrin, Jason Gotlib, Everett H Meyer

Blood (2021) 138 (Supplement 1): 1819.

https://doi.org/10.1182/blood-2021-150521

Published: 2021

Journal Articles

Engineering Human Invariant Natural Killer T (iNKT) Cells to Overexpress Immunomodulatory Cytokines

Melissa Mavers, Derek Hollingsworth, Chaiyaporn Boonchalermvichian, Jeffrey Liu, Jeanette Baker, Teresa Lopes Ramos, Juliane K. Lohmeyer, Po-Yu Lin, Maria Grazia Roncarolo, Robert S. Negrin

Blood (2021) 138 (Supplement 1): 3888.

https://doi.org/10.1182/blood-2021-153975

Published: 2021

Journal Articles

Orca-T Results in High Gvhd-Free and Relapse-Free Survival Following Myeloablative Conditioning for Hematological Malignancies: Results of a Single Center Phase 2 and a Multicenter Phase 1b Study

Blood (2021) 138 (Supplement 1): 98.

https://doi.org/10.1182/blood-2021-154191

Published: 2021

Journal Articles

CD22-CAR T-Cell Therapy Mediates High Durable Remission Rates in Adults with Large B-Cell Lymphoma Who Have Relapsed after CD19-CAR T-Cell Therapy

Blood (2021) 138 (Supplement 1): 741.

https://doi.org/10.1182/blood-2021-152145

Published: 2021

Journal Articles

Prevention of Acute Graft-Versus-Host Disease Using an Engineered Mouse Orthogonal IL-2/IL-2Rβ Regulatory T Cells

Teresa Lopes Ramos, Sara B. Wagers, Po-Yu Lin, Toshihito Hirai, Leon Su, Lora Picton, Jeanette Baker, Juliane Lohmeyer, Melissa Mavers, Christopher Garcia, Bruce R. Blazar, Robert S. Negrin

Blood (2021) 138 (Supplement 1): 1688.

https://doi.org/10.1182/blood-2021-154123

Published: 2021

Journal Articles

Invariant natural killer T-cell subsets have diverse graft-versus-host-disease–preventing and antitumor effects

Kristina Maas-Bauer, Juliane K. Lohmeyer, Toshihito Hirai, Teresa Lopes Ramos, Furqan M. Fazal, Ulrike M. Litzenburger, Kathryn E. Yost, Jessica V. Ribado, Neeraja Kambham, Arielle S. Wenokur, Po-Yu Lin, Maite Alvarez, Melissa Mavers, Jeanette Baker, Ami S. Bhatt, Howard Y. Chang, Federico Simonetta, Robert S. Negrin

Blood (2021) 138 (10): 858–870.

https://doi.org/10.1182/blood.2021010887

Published: 2021

Includes: Supplemental data

NARROW

Extracellular Release of Damaged Mitochondria Induced By Cytotoxic Conditioning Exacerbates Graft-Versus-Host Disease

CAR19 Therapy Drives Expansion of Clonal Hematopoiesis and Associated Cytopenias

Heterogeneity of Human Invariant Natural Killer T Cells, Including Novel Naïve-like CD8 + and Temra-like CD4 - CD8 - Populations, Revealed through Single Cell RNA-Sequencing

Optimizing Outcomes with Myeloablative Conditioning in Older Patients: Efficacy and Safety of Precision Engineered Orca-T in Patients > 55 Years Old with Hematologic Malignancies

Phase 1 Trial Results for Patients with Advanced Hematologic Malignancies Undergoing Reduced Intensity Allogeneic HCT with Orca-T Donor Cell Therapy Product and Single Agent Tacrolimus

Improved outcomes for relapsed/refractory Hodgkin lymphoma after autologous transplantation in the era of novel agents

Analysis of the T-cell repertoire and transcriptome identifies mechanisms of regulatory T-cell suppression of GVHD

Prevention of acute GVHD using an orthogonal IL-2/IL-2Rβ system to selectively expand regulatory T cells in vivo

Precision-Engineered Cell Therapy Orca-T Demonstrates High Relapse-Free Survival at 1 Year While Reducing Graft-Versus-Host Disease and Toxicity

Belumosudil Combination Therapy in Refractory Chronic Graft-Versus-Host Disease

The Development of Carhlh after Axicabtagene Ciloleucel Is Associated with Poor Outcomes

Analysis of Bendamustine Lymphodepletion, CD19 CART Expansion, Safety and Efficacy in Patients with Rel/Ref Non-Hodgkin Lymphoma

Higher Rates of Severe Infection and Persistent Cytopenias in Long-Term CAR19 Responders Than after Autologous HCT: A Single Institution Study of 139 Subjects

Outcomes for Acute Myeloid Leukemia Relapse after Allogeneic Hematopoietic Cell Transplantation Remain Poor in the Modern Era

Outcomes for Myelofibrosis Patients Following Myeloablative Allogeneic Stem Cell Transplantation Using the Orca-T Graft from HLA-Matched Related and Unrelated Donors

Engineering Human Invariant Natural Killer T (iNKT) Cells to Overexpress Immunomodulatory Cytokines

Orca-T Results in High Gvhd-Free and Relapse-Free Survival Following Myeloablative Conditioning for Hematological Malignancies: Results of a Single Center Phase 2 and a Multicenter Phase 1b Study

CD22-CAR T-Cell Therapy Mediates High Durable Remission Rates in Adults with Large B-Cell Lymphoma Who Have Relapsed after CD19-CAR T-Cell Therapy

Prevention of Acute Graft-Versus-Host Disease Using an Engineered Mouse Orthogonal IL-2/IL-2Rβ Regulatory T Cells

Invariant natural killer T-cell subsets have diverse graft-versus-host-disease–preventing and antitumor effects

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only